Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.5459
-0.0042 (-0.76%)
At close: Jul 17, 2026, 4:00 PM EDT
0.5165
-0.0294 (-5.39%)
After-hours: Jul 17, 2026, 7:31 PM EDT
Galmed Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
3.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.71M |
| 60 Degrees Pharmaceuticals | 1.31M |
| GeoVax Labs | 852.28K |
| Virax Biolabs Group | 12.42K |
| Creative Medical Technology Holdings | 3.00K |
GLMD News
- 3 days ago - Galmed announces development of novel LNP cardiac targeted Aramchol formulation - TheFly
- 3 days ago - Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PRNewsWire
- 27 days ago - Galmed announces restructured acquisition terms for Colospan - TheFly
- 27 days ago - Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd. - PRNewsWire
- 5 weeks ago - Galmed to acquire Colospan in cash and stock deal - TheFly
- 5 weeks ago - Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - PRNewsWire
- 6 weeks ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 6 weeks ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly